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In the previous issue of Critical Care, Friesecke and 
colleagues demonstrate that the survival rate of patients 
with severe lactic acidosis due to metformin accumu la-
tion can be strikingly higher than expected based on the 
initial clinical evaluation [1].
Metformin is nowadays the ﬁ rst-line drug of choice for 
the treatment of adults with type 2 diabetes [2]. Th is drug 
is the sixth most frequently prescribed in the USA (>50 
million prescriptions in 2009) and is taken by almost 1.5% 
of the Italian population [3,4].
Metformin is a safe drug when correctly used in 
properly selected patients. In particular, no cases of lactic 
acidosis (a relatively common side eﬀ ect of other 
biguanide compounds) were reported in 347 trials with 
70,490 patient-years of metformin use [5]. Real life can 
diﬀ er from research settings, however, and lactic acidosis 
has been repeatedly, although rarely, observed in patients 
treated with metformin. Th e number of inquiries to the 
Swedish Poison Information Centre for metformin 
intoxi cation has increased 10 times during the past 
decade, with 25 cases of severe lactic acidosis reported in 
2007 and 2008 [6]. According to the American Asso cia-
tion of Poison Control Centers, metformin may have 
contributed to 21 fatalities in the USA in 2008 [7]. Forty-
nine cases of lactic acidosis and accidental metformin 
accumulation were reported to the Poison Control 
Centre of Pavia (Italy) from January 2005 to August 2010, 
resulting in 11 deaths. Since metformin use is constantly 
increasing – there has been a 10 to 15% rise in 
prescriptions per year in the USA and Italy [3,4] – related 
cases of lactic acidosis may become less rare.
Th e term metformin-associated lactic acidosis refers to 
any case of lactic acidosis that develops in a patient 
treated with metformin, with no further mechanistic 
insight. In most of the cases, however, lactic acidosis 
cannot be directly attributed to metformin use but rather 
depends on concomitant low cardiac output, anemia, 
hypoxemia or liver failure. Th e term metformin-induced 
lactic acidosis speciﬁ cally refers to cases that cannot be 
explained by any major risk factor other than metformin 
overdose [8]. Th e distinction between these two entities 
is sometimes very subtle and metformin accumulation 
may coexist with other risk factors, all contributing to the 
pathogenesis of lactic acidosis.
Th e present case series includes 10 patients admitted to 
intensive care with lactic acidosis and metformin accu-
mu lation due to renal failure [1]. At admission, arterial 
pH was 6.75  ±  0.13 and lactatemia was 19  ±  5  mmol/l. 
Th e Simpliﬁ ed Acute Physiology Score II was 88 ± 23 and 
the predicted mortality was 96%. Eight (80%) patients 
had a cardiac arrest during their stay in intensive care. 
Treatment consisted of vital function support and renal 
replace ment therapy. Despite the dramatic severity of 
clinical presentation, hospital survival was 50%. 
Conversely, there were no survivors out of 31 patients 
with similarly severe lactic acidosis from other causes 
(mainly cardiogenic, septic or hemorrhagic shock) who 
were admitted to the same institution during the same 
period of time.
Th is ﬁ nding is in line with previous observations. In 49 
patients treated with metformin who developed severe 
lactic acidosis, survival was 17% among those with no 
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drug accumulation (that is, lactic acidosis was actually 
due to another precipitating event) and was 71% in those 
with metformin accumulation, despite a similar severity 
of hyperlactatemia [8]. In another series, one out of 10 
(10%) patients with lactic acidosis probably due to 
metformin accumulation actually died despite an initially 
predicted mortality of around 55% [9]. We have recently 
reviewed the data for 24 critically ill patients with lactic 
acidosis and proven or probable metformin intoxi cation. 
Despite an expected mortality of 70%, observed mortality 
was 21%. Even patients with initial arterial pH down to 
6.62, lactatemia up to 33 mmol/l or Simpliﬁ ed Acute 
Physiology Score II as high as 87 managed to survive to 
hospital discharge [10].
Th at lactic acidosis carries a poor prognosis has been 
known for decades [11]. Lactic acid per se, however, is 
unlikely to be the explanation for this association. Lactate 
production is indeed an adaptive response to impending 
energy failure. Th is response provides some energy and a 
chance for cells to survive, even when oxygen availability 
or utilization are defective [12]. Cancer cells in a way 
provide the best evidence for lactate overproduction 
being an eﬃ  cient response to hypoxia. By mainly relying 
on anaerobic metabolism, malignant cells can not only 
survive but even proliferate in a hypoxic environment, so 
that tumor growth can exceed angiogenesis [13]. 
According to the theory of lactate shuttles proposed by 
Brooks, lactate may act as an oxidative substrate 
exchanged between cells and tissues [14]. Acidosis itself 
may arise as an adaptive response to inadequate energy 
provision and may extend cellular viability [15].
Th e prognosis of lactic acidosis primarily depends on 
the underlying mechanism and on its reversibility. When 
lactic acidosis is due to metformin accumulation, then 
renal replacement therapy can eﬃ  ciently remove the 
toxic substance (that is, metformin and not lactate!) and 
prognosis can be surprisingly good. Th e situation can be 
much more complex and less easily reversible when lactic 
acidosis is primarily due to severe hypoxia or tissue 
hypoperfusion.
Based on present and past observations, one may 
conclude that the decision to treat (or not to treat) a 
patient with suspected metformin-induced lactic acidosis 
cannot be based only on the severity of clinical 
presentation. We personally believe that treatment of the 
critically ill patient should always include drug removal, 
as long as metformin accumulation is thought to be 
responsible for severe lactic acidosis. Since a plasma 
metformin dosage is rarely available in most centers, 
intoxication should be considered highly probable when-
ever lactic acidosis and renal failure are un commonly 
severe, other primary explanations are not evident and 
chronic metformin use is reported.
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